Claudio Viscoli

Claudio Viscoli

Auto-generated profile, based on publicly available information

Claudio Viscoli

Infectious Diseases Unit, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1999 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CVC. Viscoli
C. Viscoli
CGC. Girmenia
C. Girmenia
AMA. Marinus
A. Marinus
LCL. Collette
L. Collette
PMP. Martino
P. Martino
TEthe Invasive Fungal Infection Group of the EORTC
the Invasive Fungal Infection Group of the EORTC
In a surveillance study of candidemia in cancer patients that was conducted by the European Organization for Research and Treatment of Cancer, 249 ep

15 March 2004 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CVClaudio Viscoli
Claudio Viscoli
MMMarco Machetti
Marco Machetti
PCPaola Cappellano
Paola Cappellano
BBBarbara Bucci
Barbara Bucci
PBPaolo Bruzzi
Paolo Bruzzi
ABAndrea Bacigalupo
Andrea Bacigalupo
At the bone marrow transplantation center of the San Martino Hospital (Genoa), we observed an increase in the rate of patients with positive Platelia

1 April 2005 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CVClaudio Viscoli
Claudio Viscoli
OVOliviero Varnier
Oliviero Varnier
MMMarco Machetti
Marco Machetti
Determinations of the type and setting of empirical therapy for immunocompromised patients with fever are complicated by the characteristics of the u

15 July 2016 in World Journal of Emergency Surgery
Verified
Journal Article
Open access
PDF file
Massimo SartelliMassimo Sartelli
Massimo Sartelli
DWDieter G. Weber
Dieter G. Weber
ERETIENNE RUPPE
ETIENNE RUPPE
MBMatteo Bassetti
Matteo Bassetti
BWBrian J. Wright
Brian J. Wright
PVPerluigi Viale
Perluigi Viale
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients. The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy. Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance. The overuse of antimicrobials is widely accepted as a major driver of some emerging infections (such as C. difficile), the selection of resistant pathogens in individual patients, and for the continued development of antimicrobial resistance globally. The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria. An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials for patients with IAIs. The project has been termed AGORA (Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections). The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.

19 October 2009 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CVC. Viscoli
C. Viscoli
RHRaoul Herbrecht
Raoul Herbrecht
HAH. Akan
H. Akan
LBL. Baila
L. Baila
ASA. Sonet
A. Sonet
OEon behalf of the Infectious Disease Group of the EORTC
on behalf of the Infectious Disease Group of the EORTC
Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified intention to treat (MITT) group; secondary endpoints were response and survival at day 84 and safety. In the MITT group (n = 61), 75% of patients had cancer not in remission (relapsing or refractory), 85% were neutropenic at enrolment and 49% had a Karnofsky score of ≤50. At end of treatment, 1 and 19 patients had complete and partial response, respectively [success rate 33% (20/61)], 9 (15%) achieved stabilization and 31 (51%) had disease progression. One patient was not evaluable. The 6 and 12 week survival rates were 66% (40/61) and 53% (32/60), respectively. Baseline characteristics associated with survival at day 84 were an underlying disease in remission (not relapsing or refractory) and Karnofsky score. Recovery from neutropenia at the end of treatment was also significantly associated with survival. No serious drug-related adverse events or discontinuations due to drug-related adverse events were observed. Caspofungin provided an observed response rate compatible with the null hypothesis of a true response rate of ≤35%. Underlying disease-related factors had a major impact on results.

1 April 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
CVClaudio Viscoli
Claudio Viscoli
MMMarco Machetti
Marco Machetti
PGPaola Gazzola
Paola Gazzola
AMAndrea De Maria
Andrea De Maria
DPDimitri Paola
Dimitri Paola
ABAndrea Bacigalupo
Andrea Bacigalupo
The Aspergillus galactomannan test was performed on cerebrospinal fluid and serum samples from 5 patients with probable cerebral aspergillosis and from 16 control patients. Cerebrospinal fluid galactomannan levels were significantly higher in aspergillosis patients, and most galactomannan was produced intrathecally. Comparison of serum galactomannan values in pulmonary and cerebral aspergillosis patients showed significant overlapping. Detection of Aspergillus galactomannan in cerebrospinal fluid may be diagnostic of cerebral aspergillosis.